Form 4: Gyre Therapeutics Executive Trades Shares

Gyre Therapeutics Chief Operating Officer Ye Weiguo reported transactions involving the acquisition and disposition of company stock.

Summary

• Ye Weiguo, Chief Operating Officer of Gyre Therapeutics, Inc., engaged in several transactions involving the company's common stock on May 18th and May 19th, 2026.
• On May 18, 2026, 200 shares of common stock were acquired at a price of $0.75 per share, and 200 shares were sold at a weighted average price of $6.62.
• On May 19, 2026, 9,120 shares of common stock were acquired at a price of $0.75 per share, and 9,120 shares were sold at a weighted average price of $6.37.
• These transactions involved vested stock options, with the acquisition price of $0.75 reflecting the exercise price of the options.
• Following these transactions, Ye Weiguo beneficially owns 700,000 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine executive stock transactions rather than significant strategic news or financial performance indicators.

Positives

• Acquisition of 9,320 shares of common stock at a favorable price of $0.75 per share, indicating potential confidence in future stock value.
• Vested stock options were exercised, suggesting the executive is realizing value from their compensation package.

Negatives

• Disposition of 9,320 shares of common stock, indicating a reduction in the executive's direct holdings.
• Sales occurred at prices significantly higher than the acquisition price, suggesting profit-taking by the executive.

Risks

• The filing does not explicitly mention any risks associated with these transactions.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Management Comments

• The reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the Issuer, or a security holder.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The pattern of exercising options and selling shares is common for executives to diversify holdings or realize compensation, but significant sales can sometimes be interpreted by the market as a lack of confidence, depending on the volume and context.

Stakeholder Impact

• Shareholders may observe these transactions as part of normal executive compensation realization, but significant sales could lead to short-term market sentiment shifts.

Next Steps

• The reporting person may provide further details on share sales at specific prices upon request.

Key Dates

Keywords

Gyre Therapeutics, Form 4, Insider Trading, Stock Options, Common Stock, Executive Transactions, Beneficial Ownership, SEC Filing